Intrinsiqq
Lakewood-Amedex Biotherapeutics, Inc. logo

Lakewood-Amedex Biotherapeutics, Inc. Quality Score

LABT

Compare
Quality0

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-0.0x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-0.1x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Capital Structure
0/100
$1M

Positive debt with no FCF to service it

2024
$681098
$272862
2025
$236400
$2.00M
CashDebt
Return on Capital
0/100
-254.4%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Lakewood-Amedex Biotherapeutics (LABT) quality: score, margins and returns

Lakewood-Amedex Biotherapeutics (LABT) scores 0/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 3 metrics each scored 0 to 100 and -254.4% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Lakewood-Amedex Biotherapeutics (LABT) a high-quality business?+

Lakewood-Amedex Biotherapeutics scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -254.4% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Lakewood-Amedex Biotherapeutics's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from LABT's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Lakewood-Amedex Biotherapeutics scores well and where it falls behind.

What is Lakewood-Amedex Biotherapeutics's return on invested capital (ROIC)?+

Lakewood-Amedex Biotherapeutics earns about -254.4% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to LABT's margins and growth on this scorecard to judge durability.

How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with LABT

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing LABT

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.